
NOW ENROLLING

A Clinical Research Study evaluating an investigational medication in **moderate to severe**

POSTPARTUM DEPRESSION



THE HUMMINGBIRD STUDY

The Hummingbird Study is a Phase 3, randomized, double-blind trial evaluating the efficacy and safety of SAGE-547 (brexanolone [USAN]), an investigational medication, in the treatment of moderate and severe postpartum depression compared to placebo, as assessed by the Hamilton Rating Scale for Depression (HAM-D).

KEY INCLUSION CRITERIA:

- Women ages 18-45 years and ≤ 6 months postpartum
- Had a major depressive episode (MDE) that began no earlier than the third trimester and no later than the first 4 weeks following delivery*
- Must be amenable to IV therapy and a 3-day, in-patient treatment period
- Willing to temporarily cease breastfeeding for 7 days, starting immediately before the in-patient period

KEY EXCLUSION CRITERIA:

- Active psychosis
- Attempted suicide associated with index case of postpartum depression. Suicidal ideation is not an exclusion.
- Medical history of bipolar disorder

*As diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).

Note: Other protocol-defined inclusion/exclusion criteria may apply.

PATIENT INVOLVEMENT

STUDY DURATION: approximately 37 days **SCREENING PERIOD:** (≤7 days) to determine eligibility **TREATMENT PERIOD:** (3 days)

- 2.5-day (60-hour), in-patient infusion of SAGE-547 (brexanolone [USAN]) or placebo
- 12 hours of post-treatment assessments
- Patients who are breastfeeding must temporarily cease for 7 days, starting immediately before the inpatient period

FOLLOW-UP PERIOD:

Four follow-up visits after the start of the treatment period

All study-related procedures will be provided at no cost. Transportation may be provided for those who require assistance.

FOR ADDITIONAL INFORMATION, OR TO LEARN MORE ABOUT PARTICIPATING IN THE **HUMMINGBIRD STUDY**, PLEASE CONTACT:

HummingbirdStudy@Sagerx.com



www.HummingbirdPPDstudy.com